Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 14.7 EUR 0.82%
Updated: May 24, 2024

Intrinsic Value

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. [ Read More ]

The intrinsic value of one MEDCL stock under the Base Case scenario is hidden EUR. Compared to the current market price of 14.7 EUR, Medincell SA is hidden .

Key Points:
MEDCL Intrinsic Value
HIDDEN
Unlock
Worst Case
Base Case
Best Case

Valuation Backtest
Medincell SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MEDCL stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Medincell SA

Provide an overview of the primary business activities
of Medincell SA.

What unique competitive advantages
does Medincell SA hold over its rivals?

What risks and challenges
does Medincell SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Medincell SA.

Provide P/S
for Medincell SA.

Provide P/E
for Medincell SA.

Provide P/OCF
for Medincell SA.

Provide P/FCFE
for Medincell SA.

Provide P/B
for Medincell SA.

Provide EV/S
for Medincell SA.

Provide EV/GP
for Medincell SA.

Provide EV/EBITDA
for Medincell SA.

Provide EV/EBIT
for Medincell SA.

Provide EV/OCF
for Medincell SA.

Provide EV/FCFF
for Medincell SA.

Provide EV/IC
for Medincell SA.

Show me price targets
for Medincell SA made by professional analysts.

What are the Revenue projections
for Medincell SA?

How accurate were the past Revenue estimates
for Medincell SA?

What are the Net Income projections
for Medincell SA?

How accurate were the past Net Income estimates
for Medincell SA?

What are the EPS projections
for Medincell SA?

How accurate were the past EPS estimates
for Medincell SA?

What are the EBIT projections
for Medincell SA?

How accurate were the past EBIT estimates
for Medincell SA?

Compare the revenue forecasts
for Medincell SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Medincell SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Medincell SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Medincell SA compared to its peers.

Compare the P/E ratios
of Medincell SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Medincell SA with its peers.

Analyze the financial leverage
of Medincell SA compared to its main competitors.

Show all profitability ratios
for Medincell SA.

Provide ROE
for Medincell SA.

Provide ROA
for Medincell SA.

Provide ROIC
for Medincell SA.

Provide ROCE
for Medincell SA.

Provide Gross Margin
for Medincell SA.

Provide Operating Margin
for Medincell SA.

Provide Net Margin
for Medincell SA.

Provide FCF Margin
for Medincell SA.

Show all solvency ratios
for Medincell SA.

Provide D/E Ratio
for Medincell SA.

Provide D/A Ratio
for Medincell SA.

Provide Interest Coverage Ratio
for Medincell SA.

Provide Altman Z-Score Ratio
for Medincell SA.

Provide Quick Ratio
for Medincell SA.

Provide Current Ratio
for Medincell SA.

Provide Cash Ratio
for Medincell SA.

What is the historical Revenue growth
over the last 5 years for Medincell SA?

What is the historical Net Income growth
over the last 5 years for Medincell SA?

What is the current Free Cash Flow
of Medincell SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Medincell SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Medincell SA

Current Assets 39.4m
Cash & Short-Term Investments 26.8m
Receivables 11.5m
Other Current Assets 1.1m
Non-Current Assets 11.1m
Long-Term Investments 3.3m
PP&E 5.8m
Intangibles 2.1m
Other Non-Current Assets -1k
Current Liabilities 19.8m
Accounts Payable 2m
Accrued Liabilities 2m
Other Current Liabilities 15.8m
Non-Current Liabilities 56.4m
Long-Term Debt 53.2m
Other Non-Current Liabilities 3.2m
Efficiency

Earnings Waterfall
Medincell SA

Revenue
10.8m EUR
Cost of Revenue
-4.3m EUR
Gross Profit
6.6m EUR
Operating Expenses
-27.9m EUR
Operating Income
-21.4m EUR
Other Expenses
-5m EUR
Net Income
-26.4m EUR

Free Cash Flow Analysis
Medincell SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

MEDCL Profitability Score
Profitability Due Diligence

Medincell SA's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
hidden
Profitability
Score

Medincell SA's profitability score is hidden . The higher the profitability score, the more profitable the company is.

MEDCL Solvency Score
Solvency Due Diligence

Medincell SA's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
hidden
Solvency
Score

Medincell SA's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MEDCL Price Targets Summary
Medincell SA

Wall Street analysts forecast MEDCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEDCL is 18.79 EUR with a low forecast of 14.14 EUR and a high forecast of 23.1 EUR.

Lowest
Price Target
14.14 EUR
4% Downside
Average
Price Target
18.79 EUR
28% Upside
Highest
Price Target
23.1 EUR
57% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Medincell SA

Shareholder Return

MEDCL Price
Medincell SA

1M 1M
+21%
6M 6M
+141%
1Y 1Y
+121%
3Y 3Y
+47%
5Y 5Y
+110%
10Y 10Y
+100%
Annual Price Range
14.7
52w Low
5.5
52w High
15.4
Price Metrics
Average Annual Return 3.36%
Standard Deviation of Annual Returns 41.26%
Max Drawdown -70%
Shares Statistics
Market Capitalization 418.7m EUR
Shares Outstanding 29 070 600
Percentage of Shares Shorted
N/A

MEDCL Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Medincell SA Logo
Medincell SA

Country

France

Industry

Pharmaceuticals

Market Cap

418.7m EUR

Dividend Yield

0%

Description

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

Contact

OCCITANIE
Jacou
3 Rue des Freres Lumiere
+33467021367.0
https://www.medincell.com/

IPO

2018-10-08

Employees

150

Officers

CEO & Chairman of Executive Board
Mr. Christophe Douat
Chief People Officer & Member of the Management Board
Mr. Franck Pouzache
Chief Financial Officer
Stephane Postic
Head of Legal
Julie Alimi
Head of Communications
Mr. David Heuze
Head of Research & Development
Mr. Adolfo Lopez-Noriega
Show More
Chief Business Officer
Mr. Sebastien Enault
Head of Alliance & Project Management
Ms. Helen Martin
Head of Global Health Development
Ms. Quiterie De Beauregard
Chief Medical Officer
Dr. Richard Malamut M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MEDCL stock?

The intrinsic value of one MEDCL stock under the Base Case scenario is hidden EUR.

Is MEDCL stock undervalued or overvalued?

Compared to the current market price of 14.7 EUR, Medincell SA is hidden .